Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn Paterson

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Early Human Development|October 7, 2008
Connecting the developing preterm brainJeroen Dudink, Jenny L Kerr, Kathryn Paterson, et al.
Annals of Neurology|February 20, 2014
Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransductionKathryn Paterson, Stéphane Lolignier, John N Wood, et al.
Pain|February 28, 2012
Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labellingAndrew R Segerdahl, Jingyi Xie, Kathryn Paterson, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Early Human Development|October 7, 2008
Connecting the developing preterm brainJeroen Dudink, Jenny L Kerr, Kathryn Paterson, et al.
Annals of Neurology|February 20, 2014
Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransductionKathryn Paterson, Stéphane Lolignier, John N Wood, et al.
Pain|February 28, 2012
Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labellingAndrew R Segerdahl, Jingyi Xie, Kathryn Paterson, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
Pageof 1